Kato
Granisetron
Codeine
Enoxacin
 
 
 
 

Taxotere

Like bud, it sounds like the taxotere is not doing the trick.

Taxotere 3501

Prescription drugs sales contributed e 15, 168 million in net sales in 2001, an increase of 9.4% over reported sales of e 13, 871 million in 2000. Sales rose 15.9% on an activity basis. Prescription drugs are the principal products of Aventis, accounting for 86% of total core business sales in 2001 compared to 86% in 2000. Aventis has identified a group of leading products as being ``strategic brands, '' brand-name pharmaceuticals that we believe have significant growth potential, that in total generated sales of e 7, 322 million in 2001, a total increase of 38.3% over 2000 sales of e 5, 295 million + 38.2% activity variance ; . Our strategic brands, which were expanded in 2001 to include the newly launched products Ketek and Lantus, represented 48.3% of total prescription drug sales compared to 38.1% in 2000. Within this group, a collection of ``core'' strategic brands are being given top priority: the allergy treatment Allegra Telfast the anticoagulant agent Lovenox Clexane the chemotherapy agent Taxotere the cardiovascular treatment Delix Tritace the oral diabetes treatment Amaryl the long-acting insulin Lantus the antibiotic Ketek.

Peripheral neuropathy can cause clumsiness. Normal coordination depends on the peripheral nerve messages to the brain telling it the position of your arms, legs, hands, and feet. Peripheral neuropathy can interrupt these messages. The result is clumsiness or loss of coordination. Loss of information about the position of the limbs is called loss of position sense. You may have trouble buttoning your shirt without looking. You may also trip more than usual or have a tendency to drop things. Peripheral neuropathy is not a side effect of all chemotherapy drugs. Chemotherapy agents commonly used to treat lung cancer that can cause peripheral neuropathy include carboplatin Paraplatin ; , cisplatin Platinol ; , paclitaxel Taxol ; , docetaxel Taxotere ; , etoposide VePesid ; , topotecan Hycamtin ; , vinblastine Velban ; , vincristine Oncovin ; , vinorelbine Navelbine ; , and gemcitabine Gemzar ; . Of these drugs, peripheral neuropathy occurs most commonly with paclitaxel, docetaxel, cisplatin, and vincristine.
Carboplatin taxotere herceptin
Interestingly, PTEN expression was altered by neoadjuvant therapy. Compared to GS7 and Met, PCa cases treated with taxotere and GM-CSF had significantly increased PTEN expression Tables 1 and 2 ; . Only 23.5 percent of GM-CSF thal and 18.5 percent of Tax PCa had negative PTEN staining.

Taxotere doxorubicin cyclophosphamide

1. McDonnell T, Navone N, Troncoso P, et al: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urology 157: 569-574, 1997. Haldars B, Croce C. Bcl-2 is the guardian of microtubule integrity. Cancer Research 57: 229-233, 1997. Petrylak D, Shelton G, Judge R, et al: Phase I trial of docetaxel plus estramustine in androgen insensitive prostate cancer. J. Clin Oncol 17: 958-967, 1999. Shelton G, Gerson H, Zuech N, et al: Activity of docetaxel + estramustine after dexamethasone treatment in patients with androgen insensitive prostate cancer. Proc Soc Clin Oncol 17: 343a, 1998. Kreis W, Budman D, Fetten J, et al: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10: 33-38, 1999. Natale R, Zaretsky S: Phase I II trial of estramustine with taxotere or vinorelbine in patients with metastatic hormone-refractory prostate cancer. Proc Amer Soc Clin Oncol 17: 338a, 1998. Sinibaldi V, Carducci M, Moore-Cooper S, et al: A Phase II study evaluating a one day course of estramustine phosphate EMP ; and docetaxel D ; in patients with hormone refractory prostate cancer. Proc Soc Clin Oncol 18: 322a, 1999. Savarese D, Taplin M, Marchesani B, et al: A Phase II study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer: CALBG 9780. Proc Soc Clin Oncol 18: 321a, 1999. Friedland D, Cohen J, Miller R, et al: A Phase II trial of Taxotere in hormone refractory prostate cancer: Correlation of antitumor activity to phosphorylation of bcl-2. Proc Soc Clin Oncol 18: 322a, 1999. Picus J, Schultz M: A Phase II trial of docetaxel in patients with hormone refractory prostate cancer HRPC ; : Long term results. Proc Soc Clin Oncol 18: 314a, 1999. Weitzman A, Shelton G, Zuech C, et al: Phase II study of estramustine E ; combined with Docetaxel D ; in patients with androgen-independent prostate cancer AIPCA ; . Proc Soc Clin Oncol 18: 355a, 1999. We tailored the intensity of the regimen so she could handle it. Most other programs would have just said no to someone her age, " said Dr. Ratanatharathorn. "Usually people say that 60 years old is too old for this type of transplant. But we don't have an age limit. It depends on the individual patient." Of only four bone marrow transplant programs in Michigan, Karmanos Cancer Institute's program is the largest treating more patients than any other program in the state. Stem cell transplant outcomes at the Institute are consistently among the best in the nation. The Institute operates Michigan's only cord blood bank a program that collects umbilical cord blood for use in stem and tazorac.
Taxotere or taxol
Related behaviour, with career-related interventions designed and implemented to address some negative impacts. 13. Other external influences on the career behaviour of students include the.

To establish and coordinate the international fellowships program for south asia and telithromycin. The tables below give catch-up schedules and minimum intervals between doses for children who have delayed immunizations. There is no need to restart a vaccine series regardless of the time that has elapsed between doses. Use the table appropriate for the child's age.

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Vitko S et al. J Transplant 5 10 ; : 2521-30, 2005. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Vitko S et al. Transplantation 80 12 ; : 1734-41, 2005 and temodar!

The four large Herceptin adjuvant trials plan to enrol more than 12, 000 early breast cancer patients to establish its efficacy and role in the adjuvant setting, its safety profile, and the optimal duration of therapy. They were designed to address a broad range of therapeutic strategies currently used in the adjuvant setting and to investigate the benefit that Herceptin can offer to women with HER2-positive early primary breast cancer. They are attempting to address different issues associated with Herceptin use in this patient population, i.e., its efficacy in positive and or negative lymph nodes, its use in the adjuvant and neoadjuvant setting, its administration concomitantly or after chemotherapy, and the desired administration duration i.e., 1 or 2 years, weekly, or every 3 weeks ; [Table 1]. Finally, it must be borne in mind that some of the patients in this population can be cured with conventional treatment, such as anthracyclines and cyclophosphamide, alone or in combination with taxanes Taxol Bristol-Myers Squibb, USA ; or Taxotere Aventis Pharma, USA ; . Another aspect to remember is that Herceptin is a drug that has some cardiotoxicity, especially after anthracycline combination treatment and chest wall irradiation. Taxotere is usually administered as an injection at your doctor s office, hospital, or clinic and tenex. April Financial Report Mr. Prince, accompanied by Ms. Browne and Mr. Burnidge, provided a status report on the budget. He said the final story will be told in June but he was cautiously pleased with where the budget stood to date. Mr. Mathews commended Mr. Prince, Ms. Browne and Mr. Burnidge on their work. Mr. Mathews and Mr. Prince expressed mutual pleasure in working with one another.
DOCETAXEL, 20 MG TAXOTERE ; INJECTION, ELLIOTT'S B SOLUTION, 1 ML INJECTION, EPIRUBICIN HCL, 2 MG EPIRUBICIN HCL, 50MG ETOPOSIDE, 10 MG ETOPOSIDE, 100 MG. FLUDARABINE PHOSPHATE, 50 MG FLUOROURACIL, 500 MG FLOXURIDINE, 500 MG GEMCITABINE HCL, 200 MG GOSERELIN ACETATE IMPLANT, PER 3.6 MG ZOLADEX ; IRINOTECAN, 20 MG CAMPTOSAR ; IFOSFAMIDE, 1 GM MESNA, 200 MG IDARUBICIN HYDROCHLORIDE, 5 MG INJECTION, INTERFERON ALFACON-1, RECOMBINANT, 1 MCG INTERFERON, ALFA-2A, RECOMBINANT, 3 MILLION UNITS ROFERON A ; INTERFERON, ALFA-2B, RECOMBINANT, 1 MILLION UNITS INTERFERON, ALFA-N3, HUMAN LEUKOCYTE DERIVED ; , 250, 000 IU INTERFERON, GAMMA 1-B, 3 MILLION UNITS LEUPROLIDE ACETATE FOR DEPOT SUSPENSION ; , 7.5 MG LEUPROLIDE ACETATE, PER 1 MG LEUPROLIDE ACETATE IMPLANT, 65MG HISTRELIN, IMPLANT, 50MG Vantas ; MECHLORETHAMINE HYDROCHLORIDE, NITROGEN MUSTARD ; , 10 MG INJECTION, MELPHALAN HYDROCHLORIDE, 50 MG METHOTREXATE SODIUM, 5 MG METHOTREXATE SODIUM, 50 MG INJECTION, OXALIPLATIN, 0.5 MG INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG Abraxane ; PACLITAXEL, 30 MG PEGASPARGASE, PER SINGLE DOSE VIAL PENTOSTATIN, PER 10 MG PLICAMYCIN, 2.5 MG MITOMYCIN, 5 MG MITOMYCIN, 20 MG MITOMYCIN, 40 MG INJECTION, MITOXANTRONE HYDROCHLORIDE, PER 5 MG NOVANTRONE ; GEMTUZUMAB OZOGAMICIN, 5 MG INJECTION, PEMETREXED, 10 MG Alimta ; RITUXIMAB, 100 MG RITUXAN ; STREPTOZOCIN, 1 GM ZANOSAR ; THIOTEPA, 15 MG TOPOTECAN, 4 MG HYCAMTIN ; TRASTUZUMAB, 10 MG HERCEPTIN ; VALRUBICIN, INTRAVESICAL, 200 MG VALSTAR ; VINBLASTINE SULFATE, 1 MG VINCRISTINE SULFATE, 1 MG VINCRISTINE SULFATE, 2 MG VINCRISTINE SULFATE, 5 MG VINORELBINE TARTRATE, PER 10 MG NAVELBINE ; INJECTION, FULVESTRANT, 25 MG FASLODEX ; PORFIMER SODIUM, 75 MG NOT OTHERWISE CLASSIFIED, ANTINEOPLASTIC DRUGS INJECTION, EPOETIN ALPHA, FOR NON ESRD USE ; , PER 1000 UNITS PROCRIT ; INJECTION, DARBEPOETIN ALFA, 1 MCG NON-ESRD USE ; ARANESP ; FACTOR VIIa, PER UNIT 1.2 MG ; NOVOSEVEN ; INJECTION, SERMORELIN ACETATE, 1 MCG GEREF ; INJECTION, GLATIRAMER ACETATE, PER DOSE COPAXONE ; INJECTION, SERMORELIN ACETATE, 0.5MG INJECTION, UROFOLLITROPIN, 75IU BRAVELLE ; INJECTION, LEPIRUDIN, 50MG REFLUDAN ; INJECTION, INTERFERON BETA-1A, 11 MCG FOR SUBCUTANEOUS USE REBIF ; INJECTION, PEGFILGRASTIM, 1 MG NEULASTA ; INJECTION, DARBEPOETIN ALFA, 1 MCG ESRD USE ; ARANESP ; INJECTION, EPOETIN ALFA, 1000 UNITS FOR ESRD ON DIALYSIS ; PROCRIT EPOGEN ; INJECTION, ACYCLOVIR, 5 MG INJECTION, DOPAMINE HCL, 40 MG INJECTION, TREPROSTINIL, 1 MG REMODULIN ; INJECTION, NATALIZUMAB, 1 MG TYSABRI ; INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED, 1 GM INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED, 10 MG INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, NON-LYOPHILIZED, 1G INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, NON-LYOPHILIZED, 10 MG and teniposide. SHIVELY, J. MACK. SHLACHTER, ROBERT A SHOEMAKER, PHILIP H. SHORT, BRENDA C SHORT, MARGARET. SHOWERMAN, EARL R SHUCK, GLENN. SHURMAN, JERRY. SIEGEL, LYNNE F. SIGLER, MARCIA. SIHLER, JOHN C. SILBERMAN, TODD J SILVERBERG, AMELIA B SILVERBERG, DONNA. SILVEY, ARVILLA . SIMANTEL, MARCUS. SIMMONS, AUDREY JACKSON. SIMON, HERB . SIMON, MICHAEL. SIMON-MCWILLIAMS, ETHEL. SINCLAIR, REBECCA. SINEGAL, JAMES D SINGER, CLIFFORD MILO. SIRTORI, MICHAEL J. SITTEL, RICHARD D SKIDMORE, SHIRLEY A SKILLMAN, LAURIE ANN. SKILLMAN & FOGARTY PC . SKOWRON-GOOCH, ANNETTE. SLADER, DAVID L SLOVIC, ROSLYN. SMACNA PAC . SMART, WILLIAM M SMITH, ALLEN J. SMITH, BRUCE . SMITH, CAROLE . SMITH, CATHERINE MANZ . SMITH, CHRISTOPHER P SMITH, GREG . SMITH, JEFFERSON. SMITH, KENDRA. SMITH, LAWRENCE W SMITH, MOLLY. SMITH, MONICA A. SMITH, OLIVIA LEE . SMITH, PHILIP. SMITH, RONALD. SMITH, SARA H. SMITH, SHEILA T SMITH, GAMSON, DIAMOND, OLNEY. SMYTH, RONALD . SNAP NAMES. SNYDER, KENT V. SOBOL, MICHAEL R. SOENNEKER, ALOYSIUS J. SOHL, BRYAN . SOHN, HOWARD F SOHN, RICHARD F. SOKOL, LARRY N SONDLAND, GORDON. SONNENSCHEIN, PAUL H SORENG, JOHN . SOTH, COLLEEN V. SOUTH, SANDRA K SPECHT BC, INC. SPEIGHT, BARNEY H SPENCE, MARTHA. SPENDELOW, PETER. SPETTER, RUTH M SPICER-SCHNEIDER, SUNNY. SPICHER, SR., ROBERT. SPRING, LOWELL. SPRINGER, RICHARD S SPRINGER, SCOTT. SQUIER, ANNE . SQUIRE, DAVE C ST. LAURENT, JR., GEORGES C STACEY, JR., ROBERT . STADUM, SALLY T. STAFFORD, KIRK. STAHANCYK, GEARING, RACKNER & KENT, PC . STALKER, HOPE E STANDISH, EMILY . STANDRING GROVELAND INVESTMENT CO LLC . STANFORD, BRAD C STANG, NANCY J. STANISLAWSKI, MARK E STANLEY, MELISSA . STANLEY, NICHOLAS . STARKWOOD CHIROPRACTIC CLINIC. STARR, GEORGE . STEELE, LARRY . STELLWAY, DAVID L STEMLER, JAMES. STEN, FRIENDS OF. STEPHENSON-KUHN, LEIGH D STERLING, JULIE C STERNBERG, LEWIS. STEWARD, SHEREE. 100.00 000.00 100.00 1, 000.00 100.00 500.00 100.00 000.00 100.00 75.00 100.00 000.00 250.00 350.00 6, 000.00 500.00 300.00 125.00 000.00 500.00 300.00 100.00 000.00 250.00 100.00 STEWART, L.L STEWART, LASELLS M. BUD. STEWART, SHEREE. STILLGER, CHRISTINE . STINE, LISA S STITELER, DAVID W. STOEL RIVES LLP. STOKES, BETTE D STOLL, N. ROBERT. STOLL, STOLL, BERNE, LOKTING & SCHLACHTER, PC . STONEMAN, MARY. STORM, ROBERT M STOSSER, MICHAEL A. STOTT, JOHN F STOTT, PETER W STRAND, TERRY LEE. STRAUB, PATRICIA . STREISAND, BARBRA . STRONG, GEOFFREY D. STROOK STROOK LAVIN PAC . STUART, ROGER C STUBER, LARRY W. STUEBER, NANCY J SUGERMAN, DAVID F SULLIVAN, EDWARD J. SUMMERVILLE ADVISORS INC SUPPORTERS OF BOB ABRAMS. SUSSMAN, MARC . SWAIN, ELIZABETH H SWANSON, D. KEITH . SWANSON, JR., LES . SWANSON, THOMAS & COON, ATTORNEYS AT LAW . SWEET, KATHERINE A. SWINDELLS, CHARLES. T-MOBILE USA, INC TABOR, GARETH A., PHD, MD. TABOR, JANET . TADEPALLI, PRABHAKAR. TAFT, ANNE D. TALBOTT, RICHARD E. TALTON, CARL. TARLOW, NAITO & SUMMERS . TATTERSALL, ANN. TAUMAN, CHARLES S TAYLOR, RUTH GEORGA. TEACHERS' VOICE IN POLITICS, INC TEMPLETON, MARGARET J TEPFER, ESTHER . THANE W. TIENSON, P.C THEARD, M. ANGELE . THIES, BRADLEY J THOMAS, LINDA K. THOMAS, RITA E. THOMAS, T. DARRAH. THOMASON, SCOTT L THOMPSON, ESMO. THOMPSON, HARRY G. THOMPSON, HELEN MALARKEY. THOMPSON, MARY JEAN . THOMPSON, ROY B. THOMSON, KEITH . THORNBERRY, BONNIE . THORNBURGH, DAVID L THORNDIKE, JR., WILLIAM D THORP, CHERYL A. THRALL, THOMAS M. THRASHER, KENNETH. THREEMILE CANYON FARMS, LLC . THURBER, ALEX. TIKTIN, DAVID . TIKTIN, ELIZABETH . TILBURY, ELIZABETH . TIMBERLINE LODGE . TIMM, IAN. TIMMERMANN, STANLEY. TIMMINS, TIMOTHY . TIMPE, RONALD E. TODD, MURRAY. TODDERUD, ERIC. TOLL, PETER . TOLLENAAR, KENNETH . TOMEI, CAROLYN S. TOMISON, RITA A TOMLINSON, EDWARD . TOOLEY, BECKY J TOULAN, NOHAD A., PHD . TOWERS, ARTHUR . TOWNSEND, SUZANNE. TOWSLEE, TOM . TRAILBLAZER FOOD PRODUCTS. TRANSPORTATION POLITICAL EDUCATION LEAGUE . TRAVIS, CATHERINE. TREGER, THOMAS R. TRESIDDER CO., THE . TRINITY CONSULTING GROUP . TRITCAK, DENISE . TRITCH, HILDUR . TRITT, WILLIAM . TROMPKE, EDWARD. 500.00 250.00 100.00 000.00 5, 000.00 250.00 135.00 100.00 000.00 100.00 750.00 1, 000.00 100.00 2, 500.00 000.00 100.00 150.00 100.00 000.00 1, 000.00 100.00 500.00 3, 000.00 500.00 1, 500.00 000.00 1, 000.00 250.00 100.00 500.00 000.00 200.00 500.00 000.00 100.00 200.00 1, 000.00 100.00 250.00 100.00 000.00 100.00 000.00 100.00 200.00 750.00 000.00 5, 000.00 1, 000.00 200.00 100.00 300.00 000.00 250.00 199.00 1, 000.00 1, 500.00. On competition of binding as well as on other biological properties 1 ; Table 1 ; . A similar biosensor study was carried out here with B6t using the 16 cross-reactive MAbs prepared against B5t 1 ; . In this assay, anti-His antibody was covalently coupled to the biosensor chip and the protein was captured by its His tag. Next, the primary antibody was bound to the captured B6t. The secondary test ; antibody was then injected, and its binding pattern was monitored. The rationale is that if the second MAb fails to bind to 20 B6t, its epitope overlaps that recognized by the first MAb. If the second MAb binds, its epitope is independent of the epitope bound by the first MAb 1, 15 ; . Reciprocal blocking assays were carried out here with each of the 16 cross-reactive MAbs using B6t and compared with previous results for B5t Fig. 6 and 7 and tenofovir.
In the march across Asia Minor the Crusaders for the first time encountered their real enemy, the Seljuk Turks. These had previously contented themselves with an effort to slip into Nicaea, their capital, but the odds were too great and the city was allowed to fall. Now, however, with the Crusaders on the march, the superior knowledge of the country enjoyed by the Turks and their swifter horses combined to offset the numerical advantage of the Christians. For the Latins considerably outnumbered the Turks, in spite of the fact that they were so far away from home in the heart of the enemy's territory. The explanation of this anomalous situation lies in the condition of the Turkish and Moslem realm. The Caliph of Baghdad had become spiritual head of the Moslems. The Caliph of Egypt was head of the Ishmaelite section of the Moslems and bitterly opposed to the Caliph of Baghdad. Their fighting ground was Syria. Sixty years before the First Crusade, a new vitality had been injected into the Caliphate of Baghdad by the creation of the Seljuk Sultanate. These Seljuks, who were the most advanced of the Turks, had but recently taken on the Moslem faith. With all the zeal of neophytes, they devoted themselves to the spread of their religion. Under their earlier Sultans, they had extended their domain across Western Asia to the very gates of Constantinople. The second of their Sultans to rule Western Asia, Alp Arslan, had won a brilliant victory over the Eastern Empire at Manzikert in 1071, which opened Asia Minor to the Turks. Their ideas of political organization, however, were as rudimentary as those of the peoples of the West, and Asia Minor was given to a relative on the feudal basis of personal loyalty and homage to the Sultan. The vast empire of the Sultans soon became unmanageable. The third Sultan, Malik Shah, found his vassals restless and had to suppress at least one revolt. Upon his death in 1092, quarrels arose among his sons which lasted for more than a generation. During this time, the numerous feudal vassals exercised practical independence. They not only participated in the wars between the rivals, but often warred and taxotere.
Be careful not to cut yourself when you are using sharp objects such as a razor or nail cutters. Avoid contact sports or other situations where you may bruise or get injured. Taxotere may cause fluid retention which means the body is holding extra water. If this fluid retention is in the chest or around the heart it can be lifethreatening. If you notice swelling in the feet and legs or a slight weight gain, inform your doctor or nurse. In most cases, fluid retention will go away within weeks or months after your treatments are completed and tequin. Overall, there were more grade 4 toxicities in the taxotere arm, including febrile neutropenia 8 for alimta versus 5 percent for taxotere ; , infections 0 for alimta versus 1 percent for taxotere ; , fatigue 0 for alimta versus 4 percent for taxotere ; , painful breathing or shortness of breath 0 for alimta versus 7 percent for taxotere ; and pulmonary toxicity 0 for alimta versus 7 percent for taxotere.
Some of the most common grade 3 or 4 toxicities associated with alimta regardless of causality ; include anemia 8 percent vs 7 percent for taxotere fatigue 16 percent vs 17 percent for taxotere anorexia 5 percent vs 8 percent for taxotere and infection without neutropenia 6 percent vs 4 percent for taxotere and terfenadine.

Do not use taxotere if: you are allergic to any ingredient in taxotere or polysorbate 80 you have a severely low white blood cell count contact your doctor or health care provider right away if any of these apply to you and tazorac.

Taxotere and ovarian cancer

Taxotere reconstitution

Taxotee, twxotere, taxitere, taxoteere, taxot3re, tasotere, taxogere, tax9tere, taxote5e, txotere, tsxotere, taxtere, taxorere, taxptere, yaxotere, taxootere, taxktere, taxot4re, taxotwre, 6axotere, taaxotere, taxoterd, taxotree, txaotere, 5axotere, taxotfre, taxltere, taxotege, taxoterf, raxotere, haxotere, taxo6ere, taxotefe, taxoteree, taxohere, taxtoere.
Taxotere maintenance

Taxotere 3501, carboplatin taxotere herceptin, taxotere doxorubicin cyclophosphamide, taxotere or taxol and taxotere and ovarian cancer. Taxotere reconstitution, taxotere maintenance, taxotere drug and taxotere patient assistance or canadian taxotere.

 
© 2005-2007 Cheap.justfree.com, Inc. All rights reserved.